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To help reach the target of tuberculosis (TB) disease elimination
by 2050, vaccine development needs to occur now. We estimated
the impact and cost-effectiveness of potential TB vaccines in low-
and middle-income countries using an age-structured transmission
model. New vaccines were assumed to be available in 2024, to
prevent active TB in all individuals, to have a 5-y to lifetime dura-
tion of protection, to have 40–80% efficacy, and to be targeted
at “infants” or “adolescents/adults.” Vaccine prices were tiered by
income group (US $1.50–$10 per dose), and cost-effectiveness was
assessed using incremental cost per disability adjusted life year
(DALY) averted compared against gross national income per cap-
ita. Our results suggest that over 2024–2050, a vaccine targeted to
adolescents/adults could have a greater impact than one targeted
at infants. In low-income countries, a vaccine with a 10-y duration
and 60% efficacy targeted at adolescents/adults could prevent 17
(95% range: 11–24) million TB cases by 2050 and could be consid-
ered cost-effective at $149 (cost saving to $387) per DALY averted.
If targeted at infants, 0.89 (0.42–1.58) million TB cases could be
prevented at $1,692 ($634–$4,603) per DALY averted. This profile
targeted at adolescents/adults could be cost-effective at $4, $9,
and $20 per dose in low-, lower-middle–, and upper-middle–
income countries, respectively. Increased investments in adult-
targeted TB vaccines may be warranted, even if only short duration
and low efficacy vaccines are likely to be feasible, and trials among
adults should be powered to detect low efficacies.
mathematical modeling | epidemiology | threshold analysis
The bacterium Mycobacterium tuberculosis was responsible for∼8.6 million cases of tuberculosis (TB) disease and ∼1.3
million deaths in 2012 (1), of which over 80% were in low-
income countries (LICs) and middle-income countries. This burden
remains despite the widespread use of the infant TB vaccine, bacille
Calmette–Guérin (bacillus Calmette–Guérin) (2). Dramatic levels
of control are required to reach the World Health Organization
(WHO) targets of TB elimination as a public health problem by
2050 (3). Previous mathematical modeling has suggested elimi-
nation can only be achieved through the use of new vaccines (4–7).
In 2013, there were more than a dozen new TB vaccines in
clinical trials, using a large range of antigens and adjuvants (8). A
variety of modes of action and target populations are being re-
searched (9, 10). The most recent TB vaccine tested in a large-
scale phase II trial reported a nonsignificant impact on TB dis-
ease of 17.3% [95% confidence interval (CI): −31.9 to 48.2] (11).
However, such an undertaking highlights the progress that has
been made in TB vaccine clinical trials, as well as the need for
a reevaluation of the potential impact and need for increased
investment in new TB vaccines (12).
Estimates of the likely impact and cost-effectiveness of new
products before and during development are useful for informing
target product profiles and guiding product prioritization. Such
analyses of future vaccines have been undertaken for several other
diseases (13–17) but have been limited to exploring the cost-
effectiveness of infant vaccination in Asia and Sub-Saharan Africa
for TB (18–20). To inform the products and targeting that will be
most useful for achieving the 2050 elimination target (3), there is
a need to systematically estimate the impact in a wide range of
settings of a variety of potential TB vaccine profiles defined by
efficacy, duration of protection, and potential target groups (e.g.,
by age). The aim of this study was to estimate this potential impact
and cost-effectiveness for prospective TB vaccine profiles in LICs
and middle-income countries over the time horizon 2024–2050.
We used an age-structuredM. tuberculosis transmission model.
To be conservative in vaccine impact, we model an aggressive
scale-up of existing technologies before the introduction of the
new vaccine, in line with the recently approved post-2015 WHO
global TB strategy (21). New TB vaccines were assumed to be
available in 2024, to prevent active TB in infected and uninfected
individuals, to have a 5-y to lifetime duration of protection and
40–80% efficacy, and to be targeted at “infants” or “adolescents/
adults.” The former involved vaccination at birth, and the latter
involved vaccination at the age of 10 y in schools supplemented
with mass campaigns directed to those individuals aged 11 y and
older at a frequency corresponding to the duration of protection
or every 10 y (whichever was longer). These age groups were
chosen to reflect the feasibility of vaccine delivery. Infant vacci-
nation would be alongside the routine schedule, and 10-y-olds
could be reached in schools, where immunization is becoming in-
creasingly common. Mass campaigns were included as a scenario in
which all people at risk from TB could be targeted. Vaccine prices
were tiered by country income group, as measured in US dollars
($1.50–$10 per dose), and cost-effectiveness was defined as a cost
per disability adjusted life year (DALY) averted of less than the
gross national income (GNI) per capita.
Significance
To aid in prioritizing the development of tuberculosis (TB)
vaccines most likely to reach the 2050 TB elimination goal, we
estimated the impact and cost-effectiveness of a range of
vaccine profiles in low- and middle-income countries. Using
mathematical modeling, we show that vaccines targeted at
adolescents/adults could have a much greater impact on the TB
burden over a 2024–2050 time horizon than those vaccines
targeted at infants. Such vaccines could also be cost-effective,
even with relatively high vaccine prices. Our results suggest
that to achieve the 2050 elimination goals, future TB vaccine
development should focus on vaccines targeted at adolescents/
adults, even if only relatively low efficacies and short durations
of protection are technically feasible.
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We carried out two main analyses. The first estimated the
impact and cost-effectiveness of a broad range of prespecified
potential vaccine characteristics when targeted at infants or
adolescents/adults. The second analysis estimated the maximum
price per vaccine dose at which the vaccine could still be deemed
cost-effective. Full details are provided in Materials and Methods
and SI Appendix.
Results
Model Calibration (“No New Vaccine Scale-Up” Scenario). The results
from the calibration of the model to 91 countries are shown in
Fig. 1 A–C for LICs and in SI Appendix, Fig. S4 for lower middle-
income countries (LMICs) and upper middle-income countries
(UMICs). TB incidence and mortality fall rapidly between 2012
and 2020 as a result of our assumed aggressive scale-up of existing
technologies to be conservative about potential vaccine benefit.
Our fitting method incorporated uncertainty in TB/HIV natural
history parameters and WHO and United Nations (UN) estimates
of burden, which is shown as the gray areas on the graphs (Fig. 1
A–C). A summary of the natural history parameters used to
generate the calibration (posterior parameter distributions) is
shown in SI Appendix, Fig. S5.
The fitted model predicted the highest TB incidence to be in
LICs (Fig. 1 B and C). With our optimistic scale-up of TB control
(Fig. 1 B and C), TB incidence in 2050 is in line with the level
that could be achieved assuming the current global rate of de-
cline of 2% a year is continued (SI Appendix, Fig. S1), but it is
higher than the newly proposed post-2015 WHO targets for 2035
(21). The proportion of the TB burden in children (aged <15 y)
predicted by the model was 2–7%, compared with global esti-
mates of 5% in 2011 (22).
Epidemiological Impact of New TB Vaccine Introduction. When tar-
geting infants, a new TB vaccine was predicted to avert less than
12% of the TB burden in LICs across the 2024–2050 time ho-
rizon (Fig. 1D and Tables 1 and 2). This prediction is primarily
due to the fact that vaccinated cohorts do not reach the age of high
TB risk before 2050. Compared with LICs, a smaller percentage of
decrease in cases and deaths is predicted for LMICs and UMICs
due to the greater decrease in incidence prior to vaccine in-
troduction in the latter two groups (Table 2). For example, a vac-
cine with a 10-y duration of protection and 40% efficacy could
avert 1.8% (95% range: 1.1–2.9%) of cases in LICs but only 1.1%
(95% range: 0.5–2.4%) and 0.5% (95% range: 0.2–1.3%) of cases in
LMICs and UMICs, respectively.
If, instead, a vaccine was targeted at adolescents/adults, up to
70% of the TB burden could be averted (Fig. 1E and Table 2). For
example, a vaccine with 10-y duration of protection and 40% effi-
cacy targeted at adolescents/adults could avert 40% (95% range:
33–46%) of cases in LICs (Table 2). In LMICs, the percentage of
decline could be similar, but a higher absolute number of cases and
deaths could be averted (Table 2). The impact in UMICs is pre-
dicted to be smaller, because TB incidence is already low, but the
percentage of decline could still be substantial: 30% (95% range:
21–41%) of cases and 28% (95% range: 19–38%) of deaths may
be averted (Table 2).
The impact on TB incidence is highlighted in Fig. 1 D and E,
where the wave patterns in TB incidence reflect the impact of mass
campaigns (Fig. 1E). The majority of incidence cases are due to
recent infections, although there is some variation by country. When
the exact duration of vaccine protection has ended, there is a rapid
increase in the number of latent and susceptible individuals in the
population, who are vulnerable to (re)infection and subsequent
disease, causing the rapid increase in new cases.
Treatment and Productivity Costs. Our regression model for TB
treatment costs predicted that mean cost per patient varied from
$64 (95% CI: $27–$152) in the Democratic Republic of Congo to
$3,913 (95% CI: $2,266–$6,759) in Chile (SI Appendix, Table S11).
Mean multidrug-resistant (MDR) TB treatment costs in the same
two countries were $196 (95% CI: $44–$872) and $14,894 (95%
CI: $10,086–$21,995), respectively. Productivity costs per TB case
were predicted to range from $54/$162 in the Democratic Re-
public of Congo to $2,034/$6,102 in Chile for a TB/MDR-TB case
(SI Appendix, Table S14).
An infant vaccine with a 10-y duration of protection and 80%
efficacy could lead to cumulated, discounted TB treatment cost
savings of $185 million in LICs, $757 million in LMICs, and $1.6
billion in UMICs between 2024 and 2050. A similar profile ad-
olescent/adult vaccine could reduce TB and MDR-TB treatment
costs by $5.3 million in LICs, $35.6 billion in LMICs, and $133.4
billion in UMICs.
Cost-Effectiveness Estimates. When targeted at infants, with our
tiered pricing structure, only the lifelong duration of protection
vaccine profiles with high efficacy in LICs and LMICs were
considered cost-effective (Table 2). For example, a vaccine with
a 10-y duration of protection and 40% efficacy is considered not
to be cost-effective at an estimated cost per DALY averted of
$2,605 (95% range: $984–$7,105) in LICs.
In contrast, vaccines targeted at adolescents/adults are po-
tentially either cost-effective or cost-saving over the 2024–2050
time horizon (Table 2). For all income groups, vaccines with
a duration of protection greater than 5 y are predicted to be cost-
effective, and even cost-saving in UMICs. For example, in LICs,
a profile with a 5-y duration of protection and 60% efficacy is
cost-effective at an estimated cost per DALY averted of $378
(95% range: $150–$881).
A B C
D E
Fig. 1. Model calibration (A–C) and vaccine impact (D and E) in LICs. In A–C,
the median (solid black line) and 95% range (gray cloud) of model fits to
data (red, cross and range) are shown. (A) Human population size (in 1,000s)
in LICs for the years 2000–2050. (B) TB incidence (cases per 100,000 per year)
for the years 2000–2050. (C) TB mortality (deaths per 100,000 per year) for
the years 2000–2050. TB incidence (cases per 100,000 per year) for the years
2000–2050 with the median model output (black line) and vaccine profile
impact. Characteristics of efficacy (color) and duration of protection (line
type) are shown for vaccines targeted at infants (D) or adolescent/adults (E).
A vaccine targeted at infants (D) has a smaller impact on TB disease in-
cidence than one targeted at adolescents/adults (E). In E, “waves”within the
adolescent/adult incidence are due to mass campaigns.
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With the inclusion of productivity costs (SI Appendix, Table
S14), more profiles are predicted to be cost-saving (SI Appendix,
Table S4).
“Cost-Effective Vaccine Price” Analysis. The second analysis esti-
mated a lower bound on efficacies and duration for vaccines
to be considered cost-effective (dashed lines in Fig. 2). In LICs,
many of the vaccine profiles evaluated did not have a cost-
effective vaccine price when targeted at infants (Fig. 2), implying
that the price per dose could be zero and the vaccine would still
not be cost-effective because of the resources used delivering it.
Other profiles targeted at infants would also need to have a low
price: the cost-effective vaccine price per dose of a vaccine
profile with a 10-y duration of protection and 60% efficacy in
LICs is predicted to be only $0.28 [95% range: negative vaccine
price (NA) −$1.29] as is seen in Table 2 (Fig. 2). In LMICs, the
same vaccine profile could have a cost-effective vaccine price
of $0.82 (NA−$3.26), rising to $1.25 (NA−$6.84) in UMICs,
reflecting the higher averted treatment costs and GNI.
For an adolescent/adult-targeted vaccine, the price per vaccine
dose can be higher and the vaccine profile still be considered cost-
effective because it has a larger epidemiological impact, and hence
averts a greater treatment cost burden (Figs. 1, D and E, and 2). A
profile with a duration of protection of 10 y and 60% efficacy could
be cost-effective at a vaccine price per dose of $3.98 (95% range:
$2.05–$7.07), $9.04 (95% range: $4.58–$15.87), and $19.95 (95%
range: $9.25–$37.04) in LICs, LMICs, and UMICs, respectively
(Table 2).
Crucially, when targeted at adolescents/adults, all vaccine
profiles considered had a price per dose at which the vaccine
could be considered cost-effective, whereas those vaccine profiles
Table 1. Predicted total TB cases and deaths across 2024–2050
by income group without new vaccine [median (95% range)]
LIC LMIC UMIC
Total cases, millions 32 (23–44) 46 (30–87) 19 (11–32)
Total deaths, millions 4.2 (2.2–7.1) 5.0 (2.0–13.5) 0.9 (0.3–3.5)
Table 2. Impact of introduction of a new TB vaccine across 2024–2050: Percentage reduction in TB cases, cost per DALY averted (av.),
and cost-effective (CE) vaccine price, by income group, vaccine age target group, vaccine duration of protection, and vaccine efficacy
[median (95% range)]
LIC (GNI = $563) LMIC (GNI = $2,250) UMIC (GNI = $7,149)
Dur.
Eff.,
%
Reduction
in cases, %
Cost per
DALY av.,*
US $1,000s
CE vaccine
price,* US $
Reduction
in cases, %
Cost per
DALY av.,*
US $1,000s
CE vaccine
price,* US $
Reduction
in cases, %
Cost per
DALY av.,*
US $10,000s
CE vaccine
price,* US $
Infant
5 y 40 1.0
(0.6–1.6)
4.72
(1.78–12.77)
NA 0.6
(0.3–1.3)
33.11
(9.94–91.32)
NA 0.3
(0.1–0.7)
54.42
(5.84–232.15)
NA
60 1.5
(0.9–2.4)
3.09
(1.17–8.39)
NA 0.9
(0.4–2.0)
21.55
(6.60–60.68)
0.11
(NA–1.55)
0.4
(0.1–1.1)
34.87
(3.76–150.75)
0.24
(NA–3.24)
80 1.9
(1.2–3.2)
2.28
(0.87–6.24)
0.07
(NA–0.86)
1.2
(0.6–2.7)
15.82
(4.63–45.06)
0.42
(NA–2.40)
0.5
(0.2–1.4)
25.39
(2.58–110.06)
0.66
(NA–4.71)
10 y 40 1.8
(1.1–2.9)
2.61
(0.98–7.11)
NA 1.1
(0.5–2.4)
18.24
(5.32–51.85)
0.25
(NA–1.97)
0.5
(0.2–1.3)
28.63
(3.08–128.89)
0.42
(NA–4.33)
60 2.7
(1.6–4.3)
1.69
(0.63–4.60)
0.28
(NA–1.29)
1.7
(0.8–3.6)
11.62
(3.47–34.52)
0.82
(NA–3.26)
0.7
(0.3–1.9)
18.11
(1.67–80.91)
1.25
(NA–6.84)
80 3.5
(2.1–5.7)
1.22
(0.44–3.50)
0.54
(NA–1.97)
2.3
(1.1–4.8)
8.38
(2.52–25.45)
1.36
(0.06–4.50)
0.9
(0.4–2.6)
12.34
(1.06–59.97)
2.06
(NA–9.14)
Lifelong 40 6.2
(4.1–8.3)
0.65
(0.26–1.87)
1.26
(0.25–3.03)
3.9
(2.1–6.2)
5.12
(1.31–18.63)
2.39
(0.37–7.76)
1.6
(0.6–3.1)
5.38
(0.42–32.15)
3.53
(0.23–11.75)
60 8.9
(5.9–11.9)
0.40
(0.15–1.20)
2.07
(0.61–4.47)
5.7
(3.1–9.0)
2.99
(0.68–11.45)
3.97
(0.89–11.27)
2.3
(0.9–4.6)
2.75
(CS–20.33)
5.81
(0.90–18.82)
80 11.5
(7.6–15.2)
0.30
(0.08–0.83)
2.81
(1.01–5.82)
7.4
(4.0–11.7)
2.03
(0.24–8.61)
5.40
(1.49–15.06)
3.1
(1.2–6)
1.36
(CS–13.99)
8.15
(1.48–23.58)
Adult
5 y 40 23.9
(18.8–29.1)
0.63
(0.30–1.38)
1.30
(0.39–2.89)
24.3
(18.3–32)
3.50
(1.48–9.17)
3.45
(1.13–7.1)
17.5
(11.2–25.8)
2.45
(CS–11.61)
6.97
(2.39–15.87)
60 33.1
(26.3–39.7)
0.38
(0.15–0.88)
2.18
(0.85–4.27)
33.9
(26.0–43.4)
2.05
(0.79–5.75)
5.36
(2.29–9.94)
25.0
(16.3–36.1)
0.40
(CS–5.70)
10.90
(4.47–22.22)
80 40.7
(32.8–48.2)
0.26
(0.08–0.65)
2.88
(1.30–5.37)
41.9
(33.1–52.9)
1.28
(0.27–3.95)
7.08
(3.31–12.33)
31.9
(21.1–44.9)
CS
(CS–3.28)
14.69
(6.10–28.89)
10 y 40 39.6
(32.7–46.4)
0.28
(0.09–0.69)
2.73
(1.20–5.19)
39.6
(31.6–49.4)
1.53
(0.47–4.48)
6.44
(3.01–11.58)
30.4
(21.3–41.0)
CS
(CS–3.37)
13.18
(5.62–25.48)
60 52.1
(44.1–59.5)
0.15
(CS–0.39)
3.98
(2.05–7.07)
52.8
(44.0–63.4)
0.72
(CS–2.54)
9.04
(4.58–15.87)
42.4
(30.8–54.9)
CS
(CS–1.10)
19.95
(9.25–37.04)
80 61.8
(53.5–69.0)
0.07
(CS–0.24)
5.03
(2.75–8.48)
63.5
(54.9–73.5)
0.26
(CS–1.59)
11.52
(6.20–19.48)
53.0
(39.7–66.2)
CS
(CS–0.28)
25.78
(12.14–47.90)
Lifelong 40 44.1
(38.4–49.9)
0
(CS–0.13)
7.39
(3.93–12.54)
42.1
(34.6–50.9)
0.14
(CS–1.49)
13.25
(6.19–28.43)
34.4
(28.6–43.2)
CS
(CS–CS)
30.38
(13.54–55.94)
60 58.5
(52.6–64.3)
CS
(CS–0.05)
10.10
(5.67–16.47)
56.6
(48.7–65.6)
CS
(CS–0.48)
18.31
(9.12–39.20)
48.5
(41.5–57.8)
CS
(CS–CS)
41.95
(20.91–82.04)
80 70.0
(64.4–75.0)
CS
(CS–CS)
12.22
(7.00–19.82)
68.3
(61.0–76.2)
CS
(CS–0.05)
22.56
(11.23–44.06)
61.0
(53.5–69.7)
CS
(CS–CS)
54.49
(26.16–97.53)
CS, cost-saving (i.e., negative cost per DALY, the intervention was dominant); Dur., duration; Eff., efficacy; NA, negative vaccine price.
*Discounting included.
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targeted at infants did not (Fig. 2). For example, a vaccine profile
with an efficacy of 20% and a duration of protection of 10 y
could be cost-effective at vaccine prices per dose of $1.19
(95% range: $0.28–$2.66), $3.04 (95% range: $1.05–$6.35),
and $6.17 (95% range: $2.21–$13.8) in LICs, LMICs, and
UMICs, respectively.
Sensitivity and Uncertainty. A partial rank correlation coefficient
(PRCC) analysis revealed that the most influential parame-
ters on the number of TB cases averted by a vaccine were
those parameters governing case detection rates and pro-
gression to disease.
In our scenario analyses, a less optimistic TB control scale-up
scenario predicted a larger future burden of TB; hence, the
impact of the same vaccine profiles with the same coverage
would be greater (SI Appendix, Fig. S9). Overall cost-effective-
ness results were similar (SI Appendix, Table S5). A second
scenario analysis with decreasing HIV incidence found little ef-
fect of this decrease on the cost-effectiveness of the vaccine
profiles (SI Appendix, Table S6). A small number of vaccine
profiles were no longer cost-effective when HIV incidence
was decreased. This finding reflects the lower TB burden with
decreased HIV incidence, and therefore a lower impact of
a vaccine.
Discussion
In this study, we have used a calibrated transmission model of TB to
estimate the disease burden and costs of TB that could be averted
by different vaccine profiles in LICs and middle-income countries
before 2050. Our primary finding is that the number of cases and
deaths averted by a TB vaccine targeted at infants is predicted to be
substantially lower than one targeted at adolescents/adults. This
finding is highlighted in the associated cost-effectiveness analysis,
which estimates that vaccines targeted at infants would not be cost-
effective before 2050 with our assumed vaccine prices unless the
duration of protection were lifelong and the efficacy high. Mean-
while, vaccines targeted at adolescents/adults could be cost-effective
(under different pricing assumptions), or even cost-saving before
2050, if the duration of protection were 10 y or longer or the effi-
cacy were equal to or greater than 20%.
A novel TB vaccine targeted at infants has a smaller immediate
impact than one targeted at adolescents/adults due to children
having lower rates of TB notifications; lower proportions of smear-
positive pulmonary TB; and, as a consequence, a smaller contri-
bution to TB transmission (23). Thus, a vaccine targeted at infants
has both a smaller direct impact (by preventing relatively smaller
numbers of active cases) and a smaller indirect impact (due to fewer
secondary cases being prevented). Conversely, a vaccine targeted at
adolescents/adults has a high direct impact on the very population
with the greatest burden of active TB (i.e., the targeted population
of 10-y-olds vaccinated in schools and those individuals reached in
mass campaigns). A vaccine targeted at adolescents/adults will also
have a large indirect impact and is likely to prevent, before 2050,
more infant cases of TB than a vaccine targeted at infants due to the
reduction in transmission. Similarly, despite a lower efficacy in those
individuals with HIV, as assumed here, a vaccine could significantly
decrease overall TB transmission and avert the burden in both
HIV-negative and HIV-positive individuals.
As shown in other modeling studies, this work predicts a large
impact of new TB vaccines (4–7). Our approach differs in that we
explored a range of vaccine profiles, instead of comparing dif-
ferent mechanisms or different targeting strategies. A strength of
our modeling is that we calibrated data for the majority of LICs
and middle-income countries to the individual country level. The
limitation of this approach is that we only calibrated to a single
time point. We also incorporated uncertainty in vaccine pricing
by performing an analysis to combine impact and cost analysis.
Further uncertainty was included in our scenario analysis around
TB control scale-up and HIV incidence.
Our estimates were associated with a large level of uncertainty
(Fig. 1 and SI Appendix, Fig. S4). We believe that this uncertainty
is an appropriate reflection of the state of knowledge of TB
natural history, country level burden, and cost variation, as well
as uncertainty associated with predicting into the future. Due to
this uncertainty, we grouped our analysis by income group to
allow for broad conclusions to be made. Similarly, our compar-
isons between infant and adolescent/adult impact should be
interpreted as magnitudes of difference and not precise esti-
mates. Another limitation is that we assumed a homogeneous
population, which does not capture the heterogeneity in TB risk
or likelihood of being vaccinated. Thus, our cost-effectiveness
estimates may be an overestimation, but the relative impact of
infant vs. adolescent/adult vaccination is likely to remain the
same. Further modeling could explore these issues.
Because the aim of this work was to explore a range of vaccine
profiles with different vaccine characteristics and target pop-
ulations, we decided to explore only one vaccine mode of action
(to prevent active disease and not infection). This decision is in
line with vaccine candidates in active research (24), whereas
vaccines that prevent infection are considered less likely (4).
With further data on candidates and an increased understanding
of their true immunological effect, different assumptions could
be more appropriate and could be explored.
Fig. 2. Vaccine targeted at adolescents/adults can cost more per dose than
one targeted at infants and still be cost-effective. The contour plots shown
here are of the cost-effective vaccine price (US dollars) that results in the cost
per DALY for a vaccine, of a certain duration and efficacy, equal to the mean
GNI per capita. The color represents the price as indicated in the legend. The
dashed black line represents the values below which no price would be cost-
effective. For example, if given in LICs, an adolescent/adult vaccine with a 15-y
duration of protection and 60% efficacy could be cost-effective when priced
at ∼$7.
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Although vaccine coverage of infant vaccines can be predicted
with good confidence due to relatively robust routine data, it is
difficult to determine the likely coverage of the adolescent/adult
campaigns. However, for future TB vaccines, the mass delivery
option is considered the most feasible (25). We assumed that
vaccine coverage of around 75% could be achieved in the mass
campaigns, which is less than was achieved in most rubella vac-
cine campaigns targeting women of child-bearing age and in
recent meningococcal A vaccine campaigns in West Africa tar-
geting all 1- to 29-y-olds (26). If higher coverage can be obtained,
we may have underestimated the impact, or we may have over-
estimated the impact if these levels cannot be reached in mass
campaigns. The delivery costs of mass campaigns also remain
highly uncertain, along with the costs of productivity loss; thus, the
uncertainty in our cost-related estimates is a further limitation. We
did not attempt to address the debate about the feasibility of
frequent mass campaigns but chose to set 10 y as a minimum
frequency based on expert opinion. With more frequent mass
campaigns, the impact of the adolescent/adult vaccine could be
greater but the incremental costs would be higher. For vaccines
with a short duration of protection (<10 y), the mass campaign
frequency is crucial for preserving their initial impact; there is
a gradual increase in incidence following short duration of pro-
tection vaccination to the levels seen in the base case (Fig. 1E).
To be conservative in vaccine impact, in our main analysis, we
modelled an aggressive scale-up of existing technologies in line
with the recently approved WHO global TB strategy (21). A less
aggressive scale-up was explored in our scenario analysis, showing
that with lower TB control before vaccination, a new TB vaccine
would have a bigger impact, and hence be more cost-effective.
With future data, the actual improvements in health care could be
included in subsequent models before vaccine implementation.
Future models could also include increasing levels of MDR-TB.
With a future higher burden of MDR-TB, we would expect any
new TB vaccine to have a bigger impact, and hence be more cost-
effective. Further limitations of our modeling lie in our HIV
assumptions, with only late-stage HIV being captured and anti-
retroviral coverage taken as a weighted average.
A key focus of this analysis was the time horizon (2024–2050).
We decided to evaluate impact up to 2050 because this date is
the WHO elimination target date (21), and it is already far be-
yond the time horizon of most policy making. However, this time
frame meant that we did not measure the full lifetime impact of
a vaccine on all individuals vaccinated, and our results should be
seen as being specific to 2024–2050. An infant-targeted vaccine
would be more cost-effective if the time horizon were extended,
but these benefits would not help achieve the elimination goal. If
a vaccine were introduced later than 2024 or if the end date were
earlier (e.g., 2040 or 2045), our key results would remain the same.
The chance of a vaccine being cost-effective would decrease with
later vaccine introductions or earlier end dates.
The cost per DALY averted declines rapidly for higher income
countries due to the increasing treatment and productivity costs
averted. Thus, a vaccine is more likely to become cost-saving
with increasing duration of protection and efficacy in UMICs
than in LICs, despite our tiered vaccine pricing assumption. This
pattern is reflected in the higher vaccine prices that can be cost-
effective in UMICs.
Our regression analysis method for approximating treatment
and productivity costs in all study countries has been used in
previous studies (27, 28), and we consider these results to be
relatively robust estimates despite heterogeneity between stud-
ies. Less evidence is available about vaccine delivery costs, par-
ticularly for mass campaigns, and we had to make relatively
crude assumptions about this parameter. Further analysis could
investigate the costs associated with the logistical challenges of
carrying out the mass campaigns modelled here.
To address the uncertainty in vaccine price, we performed
a threshold analysis, reversing the question to find the vaccine
price that would be cost-effective by vaccine profile. This analysis
revealed that the cost-effective vaccine price for an infant-targeted
vaccine would be in a similar range to those prices charged for
other vaccines (<$10) (28, 29). Adolescent/adult-targeted vaccine
could be priced at a higher level, but still less than the price of
human papillomavirus vaccines (<$50) (30).
TB vaccines have the potential to tackle both the large latent
TB burden and the increasing levels of MDR-TB. This potential
appears largest if the vaccine is targeted at adolescents/adults,
providing further evidence, along with the report on increased ef-
ficacy against pulmonary TB in screened adults (31), for a recently
suggested strategy (32) of giving bacillus Calmette–Guérin to
screened adults. However, for those individuals already infected with
TB or other environmental Mycobacteria (i.e., who fail the screen),
there is still a need, and a large market, for a new TB vaccine.
The broader implications of our study are that increased invest-
ments in the development of TB vaccines targeted at adolescents/
adults may be rewarded with a rapid impact on TB disease. Spe-
cifically, such may be the case, even if only vaccines of short dura-
tion or low efficacy are likely to be technically feasible, suggesting
that future TB clinical trials among adults should be powered to
detect low efficacies.
Materials and Methods
Data. Demographic data were extracted from the UN population division
2010 revision (33). TB incidence and mortality by HIV status estimates were
obtained from the WHO [full methods are available in Annex 1 of the 2013
global TB report (1)], as were case detection rates and treatment success levels
(22). HIV incidence and antiretroviral coverage were extracted from the Joint
United Nations Program on HIV/AIDS (34). World Bank income group classi-
fications were used (35), and treatment costs were estimated from the liter-
ature (SI Appendix). Ninety-one LICs and middle-income countries were
included in the final analysis (>96% of the TB burden) (SI Appendix, Table S2).
Model and Analysis. We used an age- and HIV status-structured transmission
model to estimate the TB burden in a base case and a range of alternative
vaccination scenarios (SI Appendix, Fig. S3). The model was programmed in R
(36). This model was calibrated to the TB burden in 2009 and population size
in 2009 and 2050 in each of the 91 countries via Sobol sequence sampling
and approximate Bayesian computation. Natural history parameter ranges
were assumed to be the same for all countries, but TB and HIV control
parameters varied by country (SI Appendix, Tables S1 and S3). We explicitly
model only those people with late stage HIV infection (stages 3 and 4).
Generating 1,000 calibrations for each country allowed for the inclusion of
the uncertainty in both natural history parameters and data. Estimates of TB
burden between 2009 and 2050 were calculated under optimistic assump-
tions of improved TB and HIV control in each country to be conservative
about vaccine impact and to reflect ambitious WHO targets for improved TB
control (21) (Fig. 1, decline pre-2024, and SI Appendix, Figs. S1 and S2).
Country-level projections were combined to give an estimate (median and
range) of the TB burden without the introduction of a new TB vaccine, but
with bacillus Calmette–Guérin at current levels, by income group (Fig. 1). The
impact due to the introduction in 2024 of several potential TB vaccine
profiles, which differ by duration of protection and efficacy, to different
target populations was then considered in terms of cases and deaths averted.
After expert consultation, we investigated nine profiles with efficacies of
40%, 60%, or 80% and durations of protection of 5 y, 10 y, or lifelong. The
vaccine was assumed to prevent active disease in both infected and non-
infected individuals (24), and be 40% (10–70%) less effective in HIV-infected
individuals (37, 38). Vaccination was modelled as “take” (i.e., all or nothing
protection). “Efficacy” was then the proportion of all those individuals
vaccinated in whom the vaccine was 100% effective. Duration of protection
was exact. The two target populations were infants via routine vaccination
at birth and at 6 mo or adolescents/adults. The latter involved vaccination of
10-y-olds in schools with two doses given 6 mo apart and additional mass
campaigns in two rounds directed to all persons aged 11 y or older in 2024
and at a frequency corresponding to the duration of protection or 10 y
(whichever was longer). For each country, 2011 vaccine coverage of the third
dose of the diphtheria/tetanus/pertussis vaccine was used for the infant schedule
(39) and school attendance levels were used for coverage of 10-y-olds (29).
Coverage of mass campaigns was assumed to be 20% less than obtained in
rubella vaccine campaigns targeting women of child-bearing age (SI Appendix).
TB Treatment, Productivity, and Vaccine Delivery Costs. We undertook a sys-
tematic literature review on mean TB treatment cost per patient and used
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a regression analysis to extrapolate these data to all study countries (27, 28)
(SI Appendix, Table S11). Productivity costs due to TB were estimated using
the human capital method (40) by assuming a productivity loss of 2 mo or
6 mo for a case of TB or MDR-TB, respectively (41, 42) (SI Appendix, Table S14).
All costs are expressed in 2012 US dollars.
Vaccines were assumed to be delivered from a single vial with 5% wastage
(43), and with tiered pricing per dose of $1.5, $5, and $10 in LICs, LMICs, and
UMICs, respectively (44). Vaccine delivery cost per dose also varied according to
income group, ranging from $0.59–$1.72 (39) (SI Appendix, Table S7).
Cost-Effectiveness Analysis. The cost-effectiveness of a new TB vaccine was
compared with the current scenario with bacillus Calmette–Guérin only. The
analysis was undertaken from a health sector and societal perspective, with
the difference being that productivity costs were included in the latter. The
primary outcome measure was DALYs, estimated using 5 mo of disability for
TB and no age weighting (45). DALYs were calculated using the standard
formula (46) (SI Appendix). We classified a vaccine as cost-effective a priori if
the incremental cost per DALY averted, calculated as the average across all
countries in an income group, was less than the GNI per capita in 2011,
which was $563 for LICs, $2,250 for LMICs, and $7,149 for UMICs, in line with
the WHO “very cost-effective” threshold (47). Future values were discounted
at 3% a year.
Our secondary analysis determined the price at which the cost per DALY
averted equalled the average GNI per capita across all countries in an income
group (SI Appendix). A larger range of vaccine profiles was explored: 10–
100% efficacy and 5- to 25-y duration of protection. The same infant and
adolescent/adult targeting strategies were used.
Sensitivity and Uncertainty Analysis. Uncertainty in our estimates was gen-
erated by sampling from natural history parameter values and by sampling
the treatment cost value for each fit from a gamma distribution generated
from the 95% uncertainty range. The proportion of MDR-TB successfully
treatedwas also varied between 10% and 90% for each fit. To investigate the
influence of individual parameters on model outcomes, we used PRCCs. We
also assessed the sensitivity of our results in two scenarios: a less optimistic TB
control scale-up and a halving of HIV incidence (SI Appendix).
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